Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product ...

Learn more about platelets, small types of blood cells that prevent excessive bleeding and serve other important purposes.

Venous thromboembolism (VTE), comprising deep vein thrombosis and pulmonary embolism, is a major cause of morbidity and ...

Updated results from the phase 3 XTEND-1 trial were presented at ISTH, once again comparing the therapy to patients' previous treatment with clotting factor replacement.

In addition to their ability to directly inflict damage on macromolecules, ROS and RNS indirectly induce damage to tissues by activating a number of cellular stress-sensitive pathways. These ...

Small Animal Hospital, University of Glasgow, Glasgow G61 1QH, Scotland, U.K.